Advertisement

Related Videos

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Advertisement

Advertisement




Nov
02
Today In Oncology
Novel Strategy May Improve Outcomes in Patients With Treatment Resistant DLBCL
CAR T Cell Therapy May Be Effective but Unaffordable as Second Line Therapy for Patients With DLBCL
Second-Line Lisocabtagene Maraleucel May Be More Cost-Effective Than Standard-Care DLBCL Therapy
Combination Targeted Therapy Produces Durable Responses in Patients With Relapsed DLBCL
Shortening FDA Mandated CAR T Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo